CAR-T LAB (Chimeric Antigen Receptor T Cells Against Relapse/Refractory Leukemia, Lymphoma And Myeloma)

Dettagli

Chi siamo

 

Responsabile scientifico:

Prof.ssa Vincenzo Maria PERRIELLO

Personale afferente:

  • Vincenzo Maria PERRIELLO   Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
  • Michela CAPURRO   Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
  • Mirco MARTANARELLI  Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
  • Alessia ABATE   Questo indirizzo email è protetto dagli spambots. È necessario abilitare JavaScript per vederlo.
  biochimica

Dove siamo

Centro Ricerche Onco-Ematologico (CREO), Blocco R, Piano 2, Piazzale Menghini 8/9, Sant’Andrea delle Fratte 06132 Perugia Italy

Cosa facciamo

Terapie innovative (Vincenzo Maria PERRIELLO in collaboration with MARTELLI lab and TIACCI lab)
    Single and Dual CAR-T cell design, generation and development for relapse/refractory leukemia, lymphoma and myeloma. Stemming from own scFv (single chain fragment variable) of newly generated monoclonal antibodies next-generation of CAR-T cells are generated in order to overcome main mechanism .
Cancerogenesi e neoplasie (Vincenzo Maria PERRIELLO)
    Generation and validation of novel monoclonal antibodies against immunotherapy targets for onco-hematological disorders. Bioinformatics docking tools are used to design peptides for mice immunization. Hybridoma technology is exploite to generate new proprietary monoclonal antibodies and derive scFv (single chain fragment variable) for immunotherapeutic purposes, such as generation of CAR-T cells or by specific antibodies.
Infiammazione e risposte del sistema immunitario (Vincenzo Maria PERRIELLO in collaboration with Radiotherapy Section and Pharmacology)
    Investigating the immunomodulatory effect of radiation bridging therapy to Chimeric Antigen Receptor T (CAR-T) cell treatment. Evaluetion of cytokines and chemokines plasma concentrations as well as changes of peripheral immune cell subpopulations before and after radiation bridging therapy, to identify possible predictive biological factors for CAR-T cell expansion, persistence and toxicity.
Medicina personalizzata (Vincenzo Maria PERRIELLO in collaboration with Tettamanti lab, Departments of Pediatrics, University Milano)
    CAR-T cell manufacturing research. Optimization of preclinical findings and innovations into CAR-T cell GMP-manufacturing from autologous or allogeniec T cells for clinical production.

Tecnologie e Strumentazione

Proteomics and Metabolomics
    Multyparametric flow cytometry, luminescence cytotoxicity detection, cytokine analyses, analysis of protein expression.
    Flow cytometer (FACS Canto II, FACS Aria), microplate reader (TECAN Spark II).
Target Identification and Validation
    CRISPR/Cas9 gene editing, gene vector engeneering and cloning and expression, transfection by electroporation, microscope analyses (immunofluorescence, immunohystochemistry on frozen sections), Lentiviral vector engeneering for T cell viral transduction.
    NEON electroporator, nucleofector IIb (Lonza), ultracentrifuges, SL2 lab for MOGM manipulation, confocal mycroscopes (Zeiss SLM-510, BioRad MRC-1024).
Pre-Clinical Models
    Car-T cell generation and exoansion, hybridoma production.
    cell culture room, SL2 lab for mOGM manipulation.

Pubblicazioni

Perriello, V. M., Rotiroti, M. C., Pisani, I., Alberti, G., Pianigiani, G., Rossi, R., ... & Tettamanti, S. (2021). CD123 and CD33 Co-Targeting By Balanced Signaling on CAR-CIK Cells Reduces Potential Off-Target Toxicity While Preserving the Anti-Leukemic Activity of Acute Myeloid Leukemia. Blood, 138, 1699.

Perriello, V. M., Falini, L., Ruggeri, L., Venanzi, A., Zei, T., Iacucci-Ostini, R., ... & Falini, B. (2022). CD19 COMPLETE OR PARTIAL LOSS IS A MAJOR MECHANISM OF RELAPSE IN DLBCL PATIENTS TREATED WITH CD19-DIRECTED CAR-T CELLS: EXPERIENCE OF PERUGIA HEMATOLOGY CENTER. In HAEMATOLOGICA (Vol. 107, pp. 93-93).

Perriello, V. M., & Falini, B. (2022). NOVEL TARGET ANTIGENS FOR CAR-T CELL THERAPY. In HAEMATOLOGICA (Vol. 107, pp. 11-12).

Saldi, S., Perriello, V., Falini, L., Ingrosso, G., Zucchetti, C., Fulcheri, C. P. L., ... & Aristei, C. (2022). Radiation therapy as bridging strategy before infusion of CAR T in non hodgkin lymphoma patients. Radiotherapy and Oncology, 170, S995-S996.

Perriello, V. M., Gionfriddo, I., Rossi, R., Milano, F., Mezzasoma, F., Marra, A., ... & Brunetti, L. (2021). CD123 is consistently expressed on NPM1-mutated AML cells. Cancers, 13(3), 496.

Rotiroti, M. C., Arcangeli, S., Casucci, M., Perriello, V., Bondanza, A., Biondi, A., ... & Biagi, E. (2017). Acute myeloid leukemia targeting by chimeric antigen receptor T cells: bridging the gap from preclinical modeling to human studies. Human gene therapy, 28(3), 231-241.

Rotiroti, M. C., Buracchi, C., Arcangeli, S., Galimberti, S., Valsecchi, M. G., Perriello, V. M., ... & Tettamanti, S. (2020). Targeting CD33 in chemoresistant AML patient-derived xenografts by CAR-CIK cells modified with an improved SB transposon system. Molecular Therapy, 28(9), 1974-1986.